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Antisense noncoding RNAs are rapidly
emerging as locus-specific regulators of
gene expression in mammalian cells.
Yamanaka et al. show that the antisense
noncoding RNA Lrp1-AS negatively
regulates Lrp1 expression by binding to
Hmgb2 and inhibiting Hmgb2-mediated
Srebp1a transcriptional activation of
Lrp1. Moreover, they show discordant
dysregulation of LRP1-AS and LRP1
expression in the brain of Alzheimer’s
disease patients.
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Long non-coding RNAs (lncRNAs), including natural
antisense transcripts (NATs), are expressed more
extensively than previously anticipated and have
widespread roles in regulating gene expression.
Nevertheless, the molecular mechanisms of action
of the majority of NATs remain largely unknown.
Here, we identify a NAT of low-density lipoprotein
receptor-related protein 1 (Lrp1), referred to as
Lrp1-AS, that negatively regulates Lrp1 expression.
We show that Lrp1-AS directly binds to high-mobility
group box 2 (Hmgb2) and inhibits the activity
of Hmgb2 to enhance Srebp1a-dependent trans-
cription of Lrp1. Short oligonucleotides targeting
Lrp1-AS inhibit the interaction of antisense transcript
and Hmgb2 protein and increase Lrp1 expression by
enhancing Hmgb2 activity. Quantitative RT-PCR
analysis of brain tissue samples from Alzheimer’s
disease patients and aged-matched controls re-
vealed upregulation of LRP1-AS and downregulation
of LRP1. Our data suggest a regulatory mechanism
whereby a NAT interacts with a ubiquitous chro-
matin-associated protein to modulate its activity in
a locus-specific fashion.INTRODUCTION
Mammalian genomes are more extensively transcribed than
expected, giving rise to thousands of long non-coding RNAs
(lncRNAs), which are defined as RNA transcripts non-coding
for protein and longer than 200 nt (Bertone et al., 2004; Birney
et al., 2007; Carninci et al., 2005; Cheng et al., 2005; Djebali
et al., 2012; Kapranov et al., 2007; Yelin et al., 2003). Among
lncRNAs, NATs have emerged as a large class of regulatory
long ncRNAs (Faghihi and Wahlestedt, 2009; Magistri et al.,
2012). NATs are reported for more than 70% of all transcriptionalunits (Katayama et al., 2005) and 20% of human genes (Cheng
et al., 2005; Yelin et al., 2003). We and others have recently
shown that functional knockdown of NATs has positive or nega-
tive influences on the expression of neighboring protein-coding
genes (Carrieri et al., 2012; Faghihi et al., 2008; Katayama
et al., 2005; Mahmoudi et al., 2009; Modarresi et al., 2012),
thus implying a critical role of NATs in the regulation of gene
expression.
LncRNAs are implicated in numerous cellular processes
ranging from pluripotency, differentiation, and cell-cycle regula-
tion and are often dysregulated in disease states, such as Alz-
heimer’s disease (AD), coronary artery disease, and cancer
(Bond et al., 2009; Faghihi et al., 2008; Guttman et al., 2011; Har-
ismendy et al., 2011; Hung et al., 2011; Pastori and Wahlestedt,
2012; Prensner et al., 2011; Velmeshev et al., 2013). Although the
mechanisms of lncRNAs as key regulators of gene expression
are yet to be fully elucidated, a common emerging theme is
that lncRNAs form RNA-protein complexes to exert their regula-
tory functions. In some cases, NATs are reported to modulate
DNA accessibility by binding to chromatin-modifying complexes
and sequestration of transcription factor, which in turn influence
gene expression (Guttman and Rinn, 2012; Pastori et al., 2010;
Rinn and Chang, 2012; Wang and Chang, 2011). Therefore, in
order to understand the function of lncRNAs, it is of crucial
importance to identify the interacting proteins.
Low-density lipoprotein receptor-related protein (LRP) 1 is a
member of the low-density lipoprotein receptor family, which
has a role in a variety of physiological processes, including the
cellular transport of cholesterol, endocytosis of ligands, and
transcytosis across the blood-brain barrier (Lillis et al., 2008).
Recently, LRP1 has been implicated in the systemic clearance
of AD amyloid-beta (Ab), and the level of LRP1 expression is crit-
ical for AD progression (Deane et al., 2008; Holtzman et al., 2012;
Kang et al., 2000; Liu et al., 2007; Shibata et al., 2000). However,
little is known about the mechanisms of LRP1 expression regu-
lation. Here, we showed that transcription of LRP1 locus gives
rise to both LRP1mRNA and a spliced NAT of LRP1 gene, which
we named LRP1-AS.We demonstrated that LRP1-AS negatively
regulates LRP1 gene expression through modulating the activity
of the non-histone chromatin modifier HMGB2, and we showedCell Reports 11, 967–976, May 12, 2015 ª2015 The Authors 967
Figure 1. Genomic Organization of the
Human LRP1 and Mouse Lrp1 Locus
(A and B) NATs, human LRP1-AS (A) and mouse
Lrp1-AS (B), are cis transcribed from the opposite
strand of human LRP1 gene on chromosome
12 and mouse Lrp1 gene on chromosome 10,
respectively. Exons 5 and 6 of LRP1 and Lrp1 are
depicted in blue boxes; the exons of LRP1-AS and
Lrp1-AS are depicted in green and violet boxes,
respectively.that LRP1-AS is elevated in the brains of AD patients, where it
might repress LRP1 expression.
RESULTS
Identification of Human and Mouse LRP1-AS
To identify putative ncRNAs associated with human and mouse
LRP1 gene, we utilized the UCSC Genome Browser to search
for Expressed Sequence Tags (ESTs) overlapping human and
mouse LRP1 gene and checked for annotated antisense RNAs
in Ensembl and AceView databases. We found ESTs from the
opposite DNA strand of exon 5 of the human LRP1 gene and
exons 5 and 6 of the mouse Lrp1 gene. In humans, these ESTs
correspond to an Ensembl annotated two-exon antisense RNA
of 645 bp (RP11-545N8.3) that we named LRP1-AS (Figure 1A).
Similarly, in mouse, these ESTs correspond to an AceView
(Thierry-Mieg and Thierry-Mieg, 2006) annotated two-exon anti-
sense RNA of 1387 bp (sloty) that we named Lrp1-AS (Figure 1B).
We found short open reading frames (ORFs) of 141 bp (15 to 155)
and 108 bp (226 to 333) in exon 2 of human LRP1-AS. We also
found short ORFs of 120 bp (388 to 507) and 117 bp (675 to
791) in exon 2 of mouse Lrp1-AS. The potential polypeptides
had no sequence similarity to any other polypeptide sequence
in the GenBank protein database and were not conserved with
any predicted polypeptide in the Protein Clusters Database or
the Conserved Domain Database. Exon 2 of Lrp1-AS directly
overlaps the exons 5 and 6 of Lrp1 by 395 bp, while exon 2 of
LRP1-AS directly overlaps the exon 5 of LRP1 by 119 bp (Fig-
ure S1A). This similar location of LRP1/LRP1-AS and Lrp1/
Lrp1-AS has been maintained throughout evolution, indicating
that this genomic arrangement might have a biological function.
In order to derive general correlation between the reciprocal
expression of LRP1 and LRP1-AS, we analyzed data from the
Developmental Transcriptome project of the BrainSpan atlas
(http://brainspan.org/) (Miller et al., 2014). This project consists
of RNaseq data profiling up to 16 cortical and subcortical regions
across the course of human brain development (13 develop-
mental stages). The analysis of these data revealed a positive
correlation between LRP1 and LRP1-AS expression across
human brain development (Pearson r = 0.6115; p < 0.0001) (Fig-
ure S1B) and a reads per kilobase per million (RPKM) value for
LRP1-AS that varies from 1 to 5.9. Depending of the total amount
of RNA present in a single cell, it has been calculated that one968 Cell Reports 11, 967–976, May 12, 2015 ª2015 The Authorscopy of a transcript per cell corresponds
to RPKMvalue between 0.5 and 5 (Morta-
zavi et al., 2008). Thus, in the humanbrain, there is approximately one transcript of LRP1-AS per
cell. We then used digital PCR (dPCR) tomeasure the expression
of Lrp1 and Lrp1-AS in the mouse brain and in variety of murine
cells available in the lab. We noticed a general positive correla-
tion between Lrp1-AS and Lrp1 expression, with Lrp1-AS ex-
pressed at a higher level in the macrophage cell line RAW264.7
and at a lower level in pancreatic beta cell line MIN6 (Figure S2).
Because of the higher expression in RAW264.7, we decided to
utilize this cell line as amodel to study themechanism of function
of Lrp1-AS.
Lrp1-AS Negatively Regulates Lrp1 Expression
To investigate a possible regulation of Lrp1 levels by Lrp1-AS,
we analyzed changes in Lrp1 levels after silencing Lrp1-AS
expression. Silencing of Lrp1-AS by two different siRNAs target-
ing non-overlap regions in exons 2 led to a significant decrease in
Lrp1-AS levels in RAW264.7 cells. We observed that the degree
of Lrp1-AS downregulation was proportional to Lrp1mRNA and
protein upregulation (Figures 2A and 2B). To confirm that knock-
down of Lrp1-AS does not induce non-specific upregulation of
other genes, we analyzed changes in Gapdh levels and found
no change. We further examined Lrp1 levels after overexpres-
sion of Lrp1-AS and observed a significant decrease in Lrp1
expression (Figure 2C). These data indicated that Lrp1-AS
negatively regulates Lrp1 expression, directly or indirectly, at
both RNA and protein levels.
Cellular stress such as nutrient deprivation is known to influ-
ence the expression of Lrp1 (Annabi et al., 2010). In our cells
after serum starvation, we observed upregulation of Lrp-AS
and downregulation of Lrp1 (Figure 2D). Together, these data
showed that changes in Lrp1-AS levels influence Lrp1 expres-
sion, and this regulationmay be triggered by nutrient deprivation.
Identification of Hmgb2 Binding to Lrp1-AS
To identify specific proteins associated with Lrp1-AS RNA,
we performed RNA chromatography on purified, in vitro-tran-
scribed, full-length Lrp1-AS RNA, and 1.7-kb Luc mRNA as a
negative control to probe nuclear extracts of RAW264.7 cells.
Isolated proteins were run on a gel and visualized with silver
staining; one differentially visible protein band was subjected
to mass spectrometry, resulting in the identification of Hmgb2
(Figure S3). Consistently, the specificity of Hmgb2 binding to
Lrp1-AS was confirmed by western blotting (WB) with specific
Figure 2. Lrp1-AS Negatively Regulates Lrp1 Levels
(A) Lrp1, Lrp1-AS, and Gapdh RNA levels after Lrp1-AS silencing by control or
two different siRNAs against Lrp1-AS in RAW264.7 cells. RNA levels were
measured by quantitative RT-PCR of 24-hr post-transfection. Control siRNA
has a sequence with no homology to any gene.
(B) WB analysis of Lrp1 and b-actin proteins in RAW264.7 cells treated with
siRNA2 against Lrp1-AS (upper). Lrp1 protein levels were densitometrically
quantified and normalized by b-actin (lower).
(C) Lrp1 and Gapdh RNA levels after overexpression of Lrp1-AS in RAW264.7
cells. Empty vector (pcDNA) serves as a negative control.
(D) Lrp1-AS, Lrp1, andGapdh RNA levels of RAW264.7 cells after 12-hr serum
starvation.
Mean ± SD (n = 3 replicates) are shown in all bar graphs in (A) to (D). **p < 0.01,
***p < 0.001 determined by ANOVA.antibody (Figure 3A). Hmgb1/2 are the most abundant Hmg pro-
teins regulating numerous cellular activities, including transcrip-
tion, and Hmgb2 is highly expressed in lymphoid organs and
testes (Ronfani et al., 2001). In the reciprocal experiment, we per-
formed RNA immunoprecipitation (RIP) of endogenous Hmgb2
from RAW264.7 cells extracts. The anti-Hmgb2 IP retrieved
associated Lrp1-AS RNA as detected by quantitative RT-PCR
(qRT-PCR), but not nonspecific Gapdh or b-actin (Figure 3B).
Direct and Specific Binding of Lrp1-AS RNA to Hmgb2
Protein
Recently, Hmgb1/2 were shown to bind to a various immuno-
genic nucleic acids, including RNA (Yanai et al., 2009). To
examine the direct interaction of Hmgb1/2 with nucleic acids,
we purified recombinant Hmgb1/2 proteins from E. coli and sub-
jected to in vitro binding assays with Lrp1-AS RNA. Hmgb1 and
Hmgb2 were precipitated by immobilized full-length Lrp1-AS
RNA, which was inhibited by free Lrp1-ASRNA in a dose-depen-
dent manner (Figure 3C, left). Hmgb1-Lrp1-AS RNA binding wasinhibited by genomic DNA, but Hmgb2-Lrp1-AS RNA binding
was not affected (Figure 3C, right), suggesting the strong and
specific binding of Hmgb2 to Lrp1-AS RNA. Moreover, we pulled
down glutathione S-transferase (GST) fusion of Hmgb2 and
found that Lrp1-AS RNA is associated with Hmgb2 protein (Fig-
ure 3D). Collectively, these experiments showed that Lrp1-AS
RNA directly and specifically binds to Hmgb2.
We and others have previously shown that some lncRNAs,
including NATs, can interact with sense transcripts and make
RNA duplex through their overlap regions (Faghihi et al., 2008;
Kretz et al., 2013). To test whether this is applied to Lrp1-AS,
we performed in vivo RNase protection assay by qRT-PCR on
Lrp1 RNA. Single-stranded RNA was digested with RNase A,
and Lrp1 RNA fragment overlapped with Lrp1-AS was protected
(Figure 3E), indicating that Lrp1 and Lrp1-AS are capable of
forming an RNA duplex at an overlapping region. To elucidate
whether the overlap region of Lrp1-AS is functional, we per-
formed RNA chromatography on two deletion mutants of Lrp1-
AS, and we observed that the fragment (636–1,388) containing
the overlap region with Lrp1 strongly bound to Hmgb2 (Figures
3F and 3G). This result prompted us to investigate whether
duplex of Lrp1-AS and Lrp1 may modulate specific binding of
Lrp1-AS to Hmgb2. Following RNA chromatography on Lrp1
fragment and in vitro-hybridized RNA fragments duplex Lrp1-
AS-Lrp1 showed that Lrp1 fragment does not bind to Hmgb2
(Figure 3H, lane 1) and that Lrp1 inhibits Lrp1-AS fragment
(636–1,388) from binding to Hmgb2 (Figure 3H, lanes 4 and 5).
These data showed that Hmgb2 interacts with the overlap region
of Lrp1-AS, but not Lrp1, and this interaction is inhibited by Lrp1.
Lrp1-AS Suppresses Hmgb2-Enhanced Activity of
Srebp1a on Lrp1 Transcription
Sterol regulatory element-binding proteins (SREBPs) are a family
of three transcription factors that regulate expression of genes
involved in lipid homeostasis and glucose metabolism (Jeon
and Osborne, 2012; Raghow et al., 2008), and Srebp1/2 are
known to interact with Hmgb1/2; their activity has been reported
to be enhanced by Hmgb1 (Najima et al., 2005). Since Srebp2
was not expressed in RAW264.7 cells (data not shown), we
focused on Srebp1a/c, which is also known to play a role in tran-
scriptional regulation of Lrp1 (Bown et al., 2011). To investigate a
possible regulation of Lrp1 by Hmgb1/2 via Srebp1a/c, we first
analyzed changes in Lrp1 levels after altering Srebp1 levels.
Silencing of Srebp1 in RAW264.7 cells led to a significant
decrease in Lrp1 levels, but not Lrp1-AS (Figure 4A). Overex-
pression of Srebp1a-flag increased Lrp1 levels (Figure 4B,
lane 2), whereas Srebp1c-flag did not change Lrp1 levels (Fig-
ure S4A). Together, these data showed that Lrp1 is positively
regulated by Srebp1a.
Next, to assess the effect of Hmgb1/2 on Srebp1 transcrip-
tional activity, we examined Lrp1 levels on overexpression of
Hmgb1/2. Hmgb2, but not Hmgb1, increased Srebp1a-depen-
dent Lrp1 upregulation (Figure 4B, lanes 3 and 4). Srebp1a and
Hmgb2 did not change Lrp1-AS levels (Figure S4B). Moreover,
Hmgb2, but not Hmgb1, amplified Srebp1a-flag-induced Lrp1
promoter activity (Figure 4C). To investigate the mechanisms
for the functional cooperation between Srebp1a and Hmgb2,
we examined their possible interactions. Reciprocal co-IP withCell Reports 11, 967–976, May 12, 2015 ª2015 The Authors 969
Figure 3. Lrp1-AS Binds to Hmgb2
(A) RNase-assisted RNA chromatography on full-
length Lrp1-AS FL in RAW264.7 nuclear extracts,
visualized by WB with specific antibody against
Hmgb2.
(B) IP with control IgG or specific antibody against
Hmgb2 from RAW264.7 lysates, visualized by WB
(left), and co-precipitated RNAs from (B) were
detected by qRT-PCR using primer pairs for Lrp1-
AS, Gapdh, or b-actin (right).
(C) In vitro pull-down of 6XHis-tagged Hmgb2 with
Lrp1-AS FL and free nucleic acids as indicated.
(D) In vitro pull-down of endogenous Lrp1-AS with
GST or GST-fused Hmgb2 from RAW264.7 nu-
clear extracts. RNAs were detected by qRT-PCR
using primer pairs for Lrp1-AS or Gapdh (right).
Equal input proteins were visualized on electro-
phoresis by Comassie Brilliant Blue (CBB) stain
(left). Mean ± SD (n = 3 replicates) are shown in all
bar graphs. *p < 0.05, **p < 0.01 determined by
ANOVA.
(E) RNase protection assay. The RNA ratios were
calculated from qRT-PCR using primer pairs for
overlap region (black arrowhead) or non-overlap
region (white arrowhead) from RAW264.7 nuclear
extracts treated with (+) or without () RNase A.
Mean ± SD (n = 3 replicates) are shown. ***p <
0.001 determined by ANOVA.
(F) Schematic illustration of deletion constructs
of Lrp1 and Lrp1-AS used for (C) and (D): Lrp1
construct contains exons 5 and 6 (395 bp) of Lrp1.
Lrp1-AS 636–1388 construct contains the overlap
region between Lrp1 and Lrp1-AS, whereas Lrp1-
AS 1–656 only contains the 50 fragment of Lrp1-AS.
(G) RNA chromatography on full-length or
fragments of Lrp1-AS, as indicated above, in
RAW264.7 nuclear extracts, followed by WT
(upper). Equal input RNAs were visualized on
electrophoresis by Agilent Bioanalyzer (lower).
(H) RNA chromatography on Lrp1-AS fragments,
Lrp1 fragment, or Lrp1-AS:Lrp1 fragments hybrid,
as indicated above, in RAW264.7 nuclear extracts,
followed by WB (upper). Equal input RNAs were
visualized on electrophoresis by Agilent Bio-
analyzer (lower).specific antibodies andWBanalysesdemonstrated interaction of
endogenous mature Srebp1 and Hmgb2 (Figures 4D and 4E).
RNA chromatography on Lrp1-AS RNA failed to detect associ-
ated Srebp1, and IP ofmature Srebp1 did not retrieve associated
Lrp1-ASRNA (Figures S4A and S4B). These showed that Hmgb2
directly binds to Srebp1a in vivo and enhances its activity.
Together, Lrp1 upregulation by Srebp1a occurred at the level
of transcription, and Hmgb2 directly enhances this regulation.
We next examined whether Lrp1-AS could affect Hmgb2- and
Srebp1a-dependent Lrp1 transcriptional activation. Overexpres-
sion of Lrp1-AS repressed the potentiating effect of Hmgb2 on
Lrp1 upregulation by Srebp1a, but not Srebp1c (Figure 4F).
Lrp1-AS decreased Lrp1 promoter activity induced by Hmgb2
and Srebp1a (Figure 4G). Chromatin IP (ChIP) showed that
Lrp1-AS depletion increased Srebp1 occupancy at two tandem
SRE-like regions within Lrp1 promoter (Figure 4H). To further
investigate this regulatory mechanism, we measured Lrp1
expression in different tissues of Hmgb2 KO mice (Figure S5A).970 Cell Reports 11, 967–976, May 12, 2015 ª2015 The AuthorsAs expected, we observed a significant decrease in Lrp1 expres-
sion in the lungs of KO mice compared with WT. Unexpectedly,
we observed an increase of Lrp1 expression in the spleen of
KO animals and no significant changes in the brain, thymus, or
testes. Srebp1 expression was significantly increased in the
spleen of KO mice (Figure S5B), thus possibly explaining the
increase of Lrp1 expression in this organ.
Collectively, these data showed that Lrp1-AS inhibits the
ability of Hmgb2 to enhance Srebp1a-dependent transcription
of Lrp1.
AntagoNAT Reveals a Functional Domain of Lrp1-AS
Interacting with Hmgb2
We have previously shown that inhibition of NATs by oligonucle-
otide (termed as antagoNATs) induces upregulation of their
sense transcripts and opens a new possibility that synthetically
engineered DNAs could interact with both nucleic acids and pro-
tein functional domains to carry out engineered regulatory roles
Figure 4. Lrp1-AS Reverses the Hmgb2-
Mediated Increase in Srebp1-Dependent
Lrp1 Expression
(A) Lrp1 and Lrp1-AS levels in RAW264.7 cells
transfected with control or Srebp1 siRNA. The
control siRNA has a sequence with no homology
to any gene. WB confirms Srebp1 silencing
(upper).
(B) Lrp1 levels after overexpression of mature
Srebp1a-Flag and/or Hmgb1-HA/2-Myc in
RAW264.7 cells (upper). Expression of exogenous
proteins was monitored by WB with the indicated
antibodies (lower). An antibody to b-actin was
used as loading control in (A) and (B).
(C) Luciferase reporter assay after co-transfection
of the Lrp1 promoter-coupled luciferase construct
(upper, pGK3-Lrp1 pro.) together with over-
expression of Srebp1-Flag and Hmgb1-HA/2-Myc
in RAW264.7 cells. Firefly luciferase activity was
normalized to Renilla luciferase activity.
(D and E) Reciprocal IP of endogenous Srebp1 or
Hmgb1/2 from RAW264.7 cells followed by WB
with the indicated antibodies. Rabbit IgG was
used as negative control.
(F) Lrp1 levels after overexpression of mature
Srebp1a-Flag and Hmgb2-Myc with or without
Lrp1-AS RNA in RAW264.7 cells.
(G) Luciferase activity after co-transfection of the
Lrp1 promoter-coupled luciferase construct
together with overexpression of mature Srebp1-
Flag and Hmgb2-Myc with or without Lrp1-AS
RNA in RAW264.7 cells. Firefly luciferase activity
was normalized to Renilla luciferase activity.
(H) Quantitative ChIP (qChIP) analysis with Srebp1
antibody or control IgG from RAW264.7 cells
transfected with control or Lrp1-AS siRNA (lower).
Diagram of the Lrp1 promoter, showing the two
tandem SREBP Responsive Elements-like motifs
(SRE-likes in upper). Mean ± SD (n = 3 replicates)
are shown in all bar graphs.*p < 0.05, **p < 0.01,
***p < 0.001 determined by ANOVA.(Modarresi et al., 2012). We also observed that antagoNATs,
which target the overlapping region between sense and anti-
sense transcripts, produced the largest response in causing an
increase in sense transcript expression (Modarresi et al., 2012).
To test whether antagoNATs could interfere the interactions of
Lrp1-AS and, either Hmgb2 or Lrp1, we designed a series of 25
antagoNATs that target Lrp1-AS, covering (‘‘walking’’) the entire
shared sequence of Lrp1-AS and Lrp-1 (Figure S6A). We
observed that antagoNAT10 significantly increased Lrp1 levels
and simultaneously decreased Lrp1-AS levels (Figure 5A). We
also used eight additional oligonucleotides, partially sharing
sequence with antagoNAT10, to more exactly determine the
potential domain of Lrp1-AS regulating Lrp1 levels, and we
observed similar effect with antagoNAT10e that was set shifting
to 30 by two bases from antagoNAT10 (Figures S6B and S6C).
We further found that locked nucleic acid (LNA)-modified anta-Cell Reports 11, 967–9goNAT10 was more efficacious in
increasing Lrp1 levels (Figure S6D). We
then performed in vivo RNase protectionassay and found that antagoNAT10 failed to change the levels
of preserved RNA (Figure 5B), indicating that the interaction be-
tween Lrp1-AS and Lrp1 was not disrupted by antagoNAT10.
This led us to test whether antagoNAT10 could modulate the
binding of Lrp1-AS to Hmgb2. Co-transfection of AntagoNAT10
reversed the effect of Lrp1-AS on Hmgb2 and Srebp1-induced
Lrp1 levels (Figure 5C, lanes 4 and 5). The addition of Antago-
NAT10, but not AntagoNAT control, efficiently inhibited Lrp1-
AS retrieval by GST-Hmgb2 (Figure 5D). Together, these results
suggests that antagoNAT against a part of the overlap region of
Lrp1-AS inhibits the interaction between Lrp1-AS and Hmgb2,
which is critical for regulating Lrp1 levels (Figure 5E).
LRP1-AS Dysregulation in AD Brain
Previous reports have shown that LRP1 levels are decreased in
AD subjects, and the level of NAT is induced by diverse cell76, May 12, 2015 ª2015 The Authors 971
Figure 5. Blocking of Lrp1-AS-Hmgb2
Interaction by antagoNATs Induces Lrp1
Expression
(A) Lrp1 and Lrp1-AS levels of RAW264.7 cells
transfected with control (Ctrl) or specific antago-
NATs against Lrp1-AS, tiling the entire overlap
region between Lrp1 and Lrp1-AS (as in Fig-
ure S6). Control antagoNAT has a sequence with
no homology to any gene.
(B) RNase protection assay. The RNA ratios were
calculated from qRT-PCR using primer pairs
for overlap region (black arrowhead) or non-over-
lap region (white arrowhead) as in Figure 3E from
RAW264.7 nuclear extracts transfected with con-
trol (Ctrl) or antagoNAT10.
(C) Lrp1 levels after overexpression of mature
Srebp1a-Flag, Hmgb2-Myc, and Lrp1-AS RNA
with control (Ctrl) or AntagoNAT10 in RAW264.7
cells.
(D) The in vitro translated Lrp1-AS was pre-
incubated with control (Ctrl) or antagoNAT10
and pulled down with recombinant GST or GST-
fused Hmgb2 as in Figure 3F. Associated Lrp1-
AS RNAs were detected by qRT-PCR. Mean ±
SD (n = 3 replicates) are shown in all bar
graphs.*p < 0.05, **p < 0.01 determined by
ANOVA.stressors and elevated in AD subjects (Bishop et al., 2010; Fa-
ghihi et al., 2008; Saxena and Caroni, 2011). This prompted us
to test whether LRP1-AS and LRP1 mRNA are dysregulated in
the brain of AD patients. To test this hypothesis, we performed
qRT-PCR using RNA extracted from the superior frontal gyrus
of AD patients and age-matched controls to measure the
expression of LRP1-AS and LRP1 mRNA. As previously re-
ported, we observed decreased expression of LRP1 mRNA
levels in AD subjects, while LRP1-AS levels were surprisingly
increased (Figures 6A and 6B).
DISCUSSION
Themultiple functions of lncRNAs are just starting to emerge, and
the mechanisms through which they mediate their functions are
subject to intense investigation. Here, we have identified a NAT,
Lrp1-AS that has a critical role in the transcriptional regulation
of Lrp1 gene. The Lrp1-AS directly binds to Hmgb2 and inhibits
Hmgb2-mediated Srebp1a transcriptional activity on Lrp1.
Lrp1-AS function is in turn regulated by Lrp1 mRNA that can
base pair with Lrp1-AS forming an RNA duplex, which prevents
the interaction between Lrp1-AS andHmgb2. Furthermore, anta-
goNATagainst specificdomain ofLrp1-AS inhibits the interaction
between Lrp1-AS and Hmgb2, suggesting a model whereby a
specific regulatory sequence of lncRNA is critical for its function.
In the nucleus, HMGBs are the most abundant regulatory pro-
teins, which dynamically interact with chromatin and influence
numerous activities, including transcription, replication, repair,
and genomic stability (Bianchi and Agresti, 2005). HMGBs affect
the chromatin fiber as architectural components by competing
with histone H1 for chromatin binding sites and weakening its972 Cell Reports 11, 967–976, May 12, 2015 ª2015 The Authorsability to restrict the access of transcription machinery to the
chromatin (Bianchi and Agresti, 2005). These HMGBs-H1 inter-
actions might facilitate nucleosome remodeling and regulate
accessibility of transcription factors to the nucleosomal DNA in
response to external stimuli. The NAT studied here interacts
with HMGB2 and may serve as cell-type-specific natural RNA
ligand to inhibit HMGB2 to exert their enhancer activities as a
specific fine tuner. These suggest that a set of NATs interacts
with ubiquitous regulatory proteins to form specific RNA-protein
complexes that coordinate cell-type-specific gene expression
patterns.
We and others provide evidence that HMGB functions as an
RNA-binding proteins in addition to its long-recognized role as
a DNA-binding protein (Yanai et al., 2009). HMGBs bind to chro-
matin without any known apparent preference for the underlying
DNA sequence; their functional specificity could depend on
direct interactions with sequence-specific transcriptional factors
and bending of the DNA target sequences. However, many pro-
teins that bind nucleic acids could be expected to display at least
modest non-specific affinity for other nucleic acids, and even
sequence-specific DNA-binding transcription factors appear to
bind RNA with at least some sequence specificity. These exam-
ples include STAT1 transcription factor inhibited by an ncRNA
in MHC expression, and TLS/FUS factor bound to RNA, which
is involved in oncogenic chromosomal translocations (Lerga
et al., 2001; Perrotti et al., 1998; Peyman, 1999). LncRNAs are
cis- or trans-regulators, which can regulate target genes expres-
sion by acting as signals, guides, or scaffolds to the chromatin
through interaction with chromatin proteins to change the epige-
netic status of genes (Guttman and Rinn, 2012; Magistri et al.,
2012; Rinn and Chang, 2012; Wang and Chang, 2011). In our
Figure 6. LRP1 and LRP1-AS Dysregulation
in AD
(A and B) Quantitative RT-PCR analysis of LRP1
(A) and LRP1-AS (B) expression in superior frontal
gyrus of 15 patients with AD and 8 control subjects
(Ctrl). The housekeeping gene b-ACTIN was used
as endogenous control; LRP1 and LRP1-AS
expression was normalized to Ctrl. ***p < 0.001
determined by ANOVA.
(C) A model proposing functional and physical
interactions between Lrp1-AS, Srebp1a, and
Hmgb2 on the Lrp1 Promoter. Hmgb2 can bind
with Srebp1a and induces Lrp1 promoter activity
containing SRE-like motifs (depicted in gray
boxes). When Lrp1-AS is depleted or treated
with antagoNATs, cooperative activation of Lrp1
expression by Hmgb2 and Srebp1a is enhanced.studies, Lrp1-AS interacts with HMGB2 and may serve as cell-
type- and locu-specific natural RNA ligand to fine tune HMGB2
activity. The specific sequence of the NAT resembles that of
the protein’s alternative target, and therefore, the NAT may
compete for the protein binding to the target. This ‘‘molecular
decoy’’ model was initially demonstrated in a study showing
regulation of E. coli CsrA activity by a regulatory RNA called
CsrB (Romeo, 1998). The regulatory RNAs can create new
signaling pathways to regulate other transcriptional targets
than those original targets. The degree of pairing of RNA-pro-
teins may provide variations on global gene expression in cells,
but exactly what regulatory mechanisms allow a NAT to bind
to proteins should be elucidated. Complementary experiments
may be needed to provide insight into the aspects of NAT
sequence required for recognition by HMGB2, and this may
make it clear whether there is specific sequence requirement
in other NATs recognized by HMGB2. Finally, our study showed
that LRP1 and LRP1-AS are discordantly dysregulated in the
brain of AD patients compared with controls, where LRP1 is ex-
pressed at a lower level and LRP1-AS at a higher level. Further
research is needed to investigate the functional implication of
LRP1-AS in the pathological processes underlying AD, but accu-
mulating findings suggest that NATs and other lncRNAs could
potentially be pursued as diagnostic markers or therapeutic tar-
gets for different human diseases.
EXPERIMENTAL PROCEDURES
Cell Culture, Animal Studies, RNA Interference, Plasmids, and
AntagoNATs
All animal experiments were performed according to protocols approved by
the Institutional Animal Care and Use Committee at The Scripps ResearchCell Reports 11, 967–9Institute. RAW264.7 cell line (TIB-71, ATCC) was
maintained in DMEM supplemented with 10%
fetal bovine serum (Atlas Biologicals) and 1%
Pen/Strep. Lrp1-AS siRNAs and control siRNA
(AM4611) were synthesized by Ambion. Srebp-1
siRNA (sc-36558) was purchased from Santa
Cruz Biotechnology. Mouse cDNAs were ampli-
fied by PCR (KOD Hot Start DNA Polymerase,
Novagen). Full-length (1–1,388 bp), 50 (1–656 bp),
and 30 (636–1,388 bp) Lrp1-AS and Luciferasegene (from pGL3 Basic Vector, Promega), 3XHA-tagged Hmgb1, and
3XMyc-tagged Hmgb2 were cloned into pcDNA3.1 vector (Invitrogen).
pcDNA3.1-Flag-tagged Srebp1a/c were kindly provided by Dr. Timothy Os-
borne (Sanford-Burnham Medical Research Institute). Cells were transfected
with 30 nM of siRNA, 100 nM of antagoNATs, or 1 mg of plasmid using Amaxa
4D-Nucleofector (Lonza) according to manufacturer’s instructions and har-
vested after 24- or 48-hr post-transfection. All oligonucleotide sequences
are listed in Table S1.
RNA Purification and qRT-PCR Analysis
Total RNA from cells was isolated with RNeasy Plus Micro Kit (QIAGEN) as per
manufacturer’s instructions and analyzed with 2100 Bioanalyzer (Agilent).
Reverse Transcription was performed using SuperScript III (Invitrogen) and
random priming. Real-time PCR was performed with TaqMan Gene Expres-
sion Assays and HT7900 sequence detection system (Applied Biosystems),
as previously described (Faghihi et al., 2008; Modarresi et al., 2012). Eukary-
otic 18S or mouse b-actin was measured for an internal control and used for
normalization. Details of the human brain samples were previously described
(Faghihi et al., 2008). For RNA protection assays, cells were lysed in standard
radioimmunoprecipitation assay (RIPA) buffer, incubated with or without
RNase A/T1 (Ambion) for 1 hr at 37C and then treated with proteinase K
(Invitrogen) for 30 min at 37C, followed by RNA extraction, as previously
described (Faghihi et al., 2008).
GST Pull-Down Assays
GST-tagged Hmgb1/2were expressed in BL21 Escherichia coli (Novagen) and
purified according to standard protocols. Each GST-fusion protein was bound
to glutathione beads (GE Healthcare) for 1chr at room temperature and then
incubated with cell lysates for 2 hr at 4C. After five washes with PBS, bound
RNAs were extracted and analyzed by qRT-PCR. For in vitro binding assay,
full-length Lrp1-AS was transcribed in vitro using MEGAscript T7 Kit (Ambion),
treated with DNase I, purified with NucAway spin columns (Ambion), and de-
natured and refolded in RNA structure buffer (Ambion). The folded RNA was
incubated with antagoNATs and GST-fusion protein for 1chr, and the complex
was captured with glutathione beads for 1chr. After five times washes with
PBS, bound RNA was extracted and analyzed by qRT-PCR.76, May 12, 2015 ª2015 The Authors 973
RNase-Assisted RNA Chromatography
Full-length or fragment in vitro-transcribed 1.38 kb Lrp1-AS RNA or 1.8 kb
fragment of Luciferase RNA was conjugated to adipic acid dehydrazide
agarose beads (Sigma-Aldrich) as described. Briefly, the complexed beads
were incubated with cell lysates for 2 hr at 37C. After five washes, bound pro-
teins were eluted with RNase A/T1 and V1 (Ambion) and visualized by Silver
Staining Kit (GE Healthcare) or detected by WB. Selected band was subjected
to mass spectrometry at The Scripps Research Institute. For RNA pull-down
assays, 100 pmol of in vitro-transcribed Lrp1-AS RNAs were conjugated to
beads and incubated with 10 pmol of recombinant 6XHis-tagged Hmgb1/2
(Prospec) in the presence of increasing amounts of free Lrp1-AS RNA
(10, 100, 300, 1,000 pmol) or genomic DNA (50, 500, 1,500, 5,000 ng) for
2 hr at 37C. After five washes, bound proteins were extracted and subjected
to WB.
WB and IP
To prepare protein lysates, cells were harvested, washed, and lysed in stan-
dard RIPA buffer. Total protein concentration was measured by Pierce
660 nm protein assay, and WB was performed according to standard proto-
cols. The quantification of signals was performed using Image J software.
For IP, cells were cross-linked with 1% formaldehyde for 10 min, followed
by the addition of glycine to a final concentration of 0.125 M. After two
washes with PBS, cells were lysed with Buffer A (10 mM HEPES [pH 7.4],
10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT supplemented with Roche Com-
plete Protease Inhibitor Cocktail), lysed in 0.25% NP40, fractionated by
low-speed centrifugation. The nuclear pellet was resuspended with Buffer
C (20 mM HEPES [pH 7.4], 420 mM KCl, 4 mM MgCl2, 0.5 mM DTT, 10%
glycerol; Roche protease inhibitor) and sonicated for 7 min with Bioruptor
UCD-200 (Diagenode). Combined nuclear and cytoplasmic fractions were
mixed with antibody and incubated for 2 hr at 4C. The complex was
captured with Protein A/G beads for 1 hr at 4C. After four times washes
with NP-40 buffer (50 mM HEPES [pH 7.4], 100 mM KCl, 5 mM MgCl2,
0.5 mM DTT, 0.1% NP-40, 10% glycerol), bound proteins were eluted in
23 Laemmli Sample Buffer and subjected to WB. For RIP, bound RNA
were extracted with Proteinase K (Ambion) in RIPA buffer for 1 hr at 45C
and analyzed by qRT-PCR. Specific antibodies in the present study include
Lrp1 (EPR3724, Novus Biologicals), Srebp-1 (H-160 for IP and ChIP, K-10
and C-20 for WB; Santa Cruz Biotechnology), Hmgb2 (H9789; Sigma-
Aldrich), Flag (M2; Sigma-Aldrich), HA.11 (16B12; Covance), c-;myc (9E10;
Covance), b-actin (AC-15; Sigma-Aldrich).
Luciferase Reporter Assays
pGL3-Lrp1 promotor (Liu et al., 2007) was kindly provided by Dr. Guojun Bu
(Mayo Clinic). Cell extracts after 24-hr transfection were assayed for firefly
and renilla (phRL-TK; Promega) luciferase activities in 96-well white plates
(Nunc) using Dual-luciferase Reporter Assay System (Promega) and EnVision
2104 Multilabel Reader (PerkinElmer).
ChIP
Cells were cross-linked with 1% formaldehyde for 10 min, followed by the
addition of glycine to a final concentration of 0.125 M. After two washes with
PBS, cells was lysed with Lysis Buffer 1 (50 mM HEPES [pH 7.4], 140 mM
NaCl, 1 mM MgCl2, 0.5% NP-40, 0.25% Triton X-100, 10% glycerol; Roche
protease inhibitor) for 10 min, followed by Lysis Buffer 2 (10 mM Tris [pH
8.0], 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA; Roche protease inhibitor)
for 10 min. Next, the nuclear pellet was sonicated for 40 min with Bioruptor
UCD-200 in Lysis Buffer 3 (20 mM Tris [pH 8.0], 300 mM NaCl, 1 mM EDTA,
0.5 mM EGTA, 0.1% sodium deoxycholate, 0.5%N-Laurorylsarcosine, Roche
protease inhibitor), and lysed in 1% Triton X-100. The nuclear fraction was
mixed with antibody and incubated overnight at 4C. The complex was
captured with sheep anti-Rabbit IgG-coupled magnetic beads (Dynabeads;
Invitrogen) for 1 hr at 4C. After one wash with Low Salt Buffer (20 mM Tris
[pH 8.0], 150mMNaCl, 2mMEDTA, 0.1%SDS, 1% Triton X-100), two washes
with High Salt Buffer (20 mM Tris [pH 8.0], 400 mM NaCl, 2 mM EDTA, 0.1%
SDS, 1% Triton X-100), five washes with RIPA Buffer and one time with TE
Buffer (50 mM Tris [pH 8.0], 10 mM EDTA) containing 50 mM NaCl, bound
DNA was reverse cross-linked in TE buffer with 1% SDS at 65C overnight974 Cell Reports 11, 967–976, May 12, 2015 ª2015 The Authorsand treated with RNase A/T1 at 55C for 30 min and following Proteinase K
at 55C for 1 hr. Bound DNA was purified and analyzed by qPCR with Power
SYBR Green Master Mix (Applied Biosystems).
Raindance Raindrop dPCR Assay
dPCR assays were performed as per manufacturer’s protocols. In brief, 50-ml
reactions were used with Applied Biosystems 2X Taqman gene expression
master mix, 203 primer probe, 253 drop stabilizer, and 100 ng of cDNA. Oil
droplets were generated on the Raindrop Source chip instrument and then
amplified on a BioRad C1000 thermocycler using the following conditions:
50C for 2 min, 95C for 10 min and 40 cycles of 95C for 15 s, 60C for
1 min, hold at 10C. Fluorescent droplets were detected on the Raindance
Raindrop Sense chip instrument and then analyzed using the Raindance Rain-
drop Analyst software v.2 to count VIC and FAM drops and to prepare output
graphs.
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